Introduction
============

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (MTB), remains a life-threatening disease and is still one of the most important causes of morbidity and mortality worldwide.[@b1-idr-12-579] In the latest World Health Organization (WHO) global report on TB,[@b2-idr-12-579] there were an estimated 1.3 million TB deaths in 2017 and an additional 300,000 deaths resulting from TB disease among HIV-positive people. The worldwide emergence of drug-resistant MTB (DR-TB), especially multi-DR TB (MDR-TB) and extensive DR-TB, is widely considered to be a serious challenge for TB control programs.[@b3-idr-12-579],[@b4-idr-12-579] MDR-TB is caused by strains of MTB that do not respond to at least both isoniazid (Inh) and rifampicin (Rif), and extensive DR-TB is defined as an MDR isolate that is also resistant to a fluoroquinolone and at least one second-line injectable agent (amikacin, kanamycin, and capreomycin).[@b3-idr-12-579] According to the WHO report, there were an estimated 558,000 cases of MDR Rif-resistant TB in 2017.[@b1-idr-12-579] As such, the rapid detection of drug resistance is essential for appropriate treatment of the disease that avoids treatment failure and prevents the spread of DR strains.[@b5-idr-12-579]

Ethambutol (Emb) is an important first-line drug that is widely used for the treatment of TB and MDR-TB.[@b6-idr-12-579],[@b7-idr-12-579] The mechanism of action of Emb is inhibition of the synthesis of the arabinan component of lipoarabinomannan and arabinogalactan in the mycobacterial cell wall.[@b8-idr-12-579] Arabinosyl transferase is encoded by the *embCAB* locus, which comprises the three genes of *embC, embA and embB. embA* and *embB* genes apparently contribute to the synthesis of arabinogalactan, whereas *embC* is reserved for the synthesis of lipoarabinomannan.[@b9-idr-12-579],[@b10-idr-12-579] Mutations in the 10 kb *embCAB* operon are associated with resistance to Emb, especially the *embB* gene.[@b11-idr-12-579] The most commonly detected mutations have occur at codons 306, 406, and 497 within the *embB* gene. Therefore, these codons represent promising diagnostic markers for the rapid detection of Emb resistance.[@b12-idr-12-579] Five distinct missense mutations are found in codon 306 with changes in the first or third base (ATG, GTG, CTG, ATA, ATC, or ATT), resulting in the replacement of methionine by three different amino acids (Met to Val, Leu, or Ile).[@b13-idr-12-579] As the *embCAB* operon (*embC*, *embA*, and *embB*) of MTB is considered involved in resistance to Emb,[@b14-idr-12-579] this study aimed to analyze the most common mutations within he *embCAB* operon among MTB isolates from Iran to find any correlation of these mutations with Emb resistance.

Methods
=======

Sample collection and bacterial strains
---------------------------------------

A total of 307 clinical isolates of MTB were detected in 906 samples during a 16-month period from February 2016 to June 2017. The samples were obtained from patients with suspected pulmonary TB diagnosed by infectious-disease specialists and referred to the regional tuberculosis laboratory of Khuzestan province, Iran. The preliminary proposal of the work was approved in joint by the institutional review board and ethics committee of Ahvaz Jundishapur University of Medical Sciences, Iran, and necessary permission was granted for sample collection. Apart from this, as part of the regional center policy, referred patients were requested to sign the informed consent in case their samples were used for research purposes apart from routine clinical investigation, and our study was conducted in accordance with the Declaration of Helsinki. Isolates were identified as MTB on the basis of acid-fast-stain microscopy, growth in modified Löwenstein--Jensen (LJ) medium, and performance of conventional biochemical tests, including niacin accumulation, nitrate reductase, and catalase at 37°C and 68°C.[@b15-idr-12-579]

Antimicrobial susceptibility testing
------------------------------------

Antimicrobial susceptibility testing (AST) for first-line anti-TB drugs was performed on LJ medium using a proportional method according to the Clinical and Laboratory Standard Institute guideline.[@b16-idr-12-579] The following critical drug concentrations were used for AST: 0.25 µg/mL for Inh, 0.02 µg/mL for Rif, and 4 µg/mL for Emb (Sigma-Aldrich, St Louis, MO, USA). H37Rv (ATCC 27294) was used as the control for AST. Susceptibility was defined as no or \<1% growth on LJ medium-containing drugs compared with the control medium.

DNA extraction
--------------

DNA was extracted from MTB grown on LJ medium by a simple boiling method as previously described.[@b17-idr-12-579] The concentration of extracted DNA was measured by biophotometry (Eppendorf, Hamburg, Germany) at 260 nm, and samples were stored at −20°C until use.

PCR amplification
-----------------

PCR amplification was performed in an Eppendorf thermocycler (Roche, Basel, Switzerland) by application of primers designed for various gene loci of *embC*, *embA*, and *embB*,[@b18-idr-12-579],[@b19-idr-12-579] as presented in [Table 1](#t1-idr-12-579){ref-type="table"}.

Amplification reactions in a total volume of 50 µL containing 5 µL 10× PCR buffer, 1.5 mM MgCl~2~, 0.2 mM dNTP mix, 0.2 µM of each primer, 2.5 U *Taq* polymerase, and 5 µL template DNA (10 ng) were prepared. Amplification conditions were: *embB* gene -- initial denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 40 seconds, primer annealing at 48°C for 30 seconds, and extension at 72°C for 30 seconds, followed by a final extension at 72°C for 5 minutes; *embA* and *embC* genes -- initial denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 40 seconds, annealing at 63°C for 30 seconds, and extension at 72°C for 30 seconds, and a final extension at 72°C for 5 minutes. H37Rv (ATCC 27294) was used as a reference strain. PCR products were loaded on a 1.5% (w:v) agarose gel with 0.5 µg/mL ethidium bromide, analyzed by gel electrophoresis, and photographed using the gel-documentation system (ProteinSimple, San Jose, CA, USA). SPSS version 16 was used for data analysis. PCR products were sent to Bioneer (Daejeon, South Korea) for sequencing.

Results
=======

From the total 906 sputa processed, 307 (33.88%) were identified as MTB on the basis of culture and biochemical criteria. These belonged to 233 men and 74 women with a mean age of 33 years. In total, 26 isolates (8.47%) showed resistance to the antimicrobial agents tested. The resistance profiles of the 307 MTB isolates according to AST were Inh 6 (1.95%), Rif 10 (3.25%), and Emb 10 (3.25%). The prevalence of MDR was four (1.30%), three of which showed coresistance to Emb ([Table 2](#t2-idr-12-579){ref-type="table"}).

The ten Emb-resistant and 28 randomly selected Emb susceptible isolates were processed for characterization of *embCAB* genes. According to the sequencing analyses, the mutation rate in the Emb-resistant MTB strains was 20% (n=2), comprising one mutation in *embB* (10%) at codon 306 Met--Val (ATG→GTG) and one in *embC* (10%) at codon 270 Thr--Ile (ACC→ATC). No mutation in *embA* was demonstrated in Emb-resistant isolates in this study ([Table 3](#t3-idr-12-579){ref-type="table"}). Only one of the MDR strains with coresistance to Emb showed a mutation in *embB*. Moreover, we noticed a nonsynonymous mutation in the *embA* gene in one of the randomly selected Emb-susceptible isolates, located in codon 330 Leu--Leu (CTG→TTG). In [Table 4](#t4-idr-12-579){ref-type="table"}, the mutations detected in all Emb-resistant and selected Emb-susceptible isolates are presented.

Discussion
==========

Emb is used as an alternative drug to streptomycin in the standard four-drug combination TB therapy; however, due to the rapid increase in Emb resistance among clinical isolates of MTB, early accurate detection of Emb resistance is essential to avoid the risk of adverse reactions, particularly optic neuritis.[@b20-idr-12-579] In this study, molecular methods based on *embCAB*-gene mutations were used to investigate the nature of Emb resistance in MTB isolates. DNA-sequencing analysis of *embCAB* loci in ten Emb-resistant and 26 Emb-susceptible isolates revealed three polymorphic nucleotide sites, each located in different regions of the three gene loci. We demonstrated only two mutations in Emb-resistant strains (20%), one a common mutation with alteration of methionine--valine at codon 306. Alterations at codon 306 of *embB* have been demonstrated as the most common alterations in Emb-resistant MTB clinical isolates.[@b19-idr-12-579],[@b21-idr-12-579] Moreover, high detection rates of mutations at codon *embB*306 among Emb-resistant MTB isolates have been reported in recent years from China (55%),[@b22-idr-12-579] Cuba and the Dominican Republic (70%),[@b23-idr-12-579] and Germany (68%).[@b24-idr-12-579]

The second mutation occurred at codon 270 of *embC*, with alteration in threonine--isoleucine. This mutation has also been described previously with less frequency among Emb-resistant isolates of MTB. We have also identified a nonsense mutation in one Emb-susceptible isolate in the *embA* gene as Leu330Leu. The region of *EmbB* containing residue Met306 is highly conserved in MTB, *Mycobacterium avium*, *Mycobacterium leprae*, and *M. smegmatis* strains,[@b25-idr-12-579] and the data generated from the Emb-susceptibility testing indicate a strong nonrandom association between certain amino-acid substitutions at *embB* position 306 and the level of resistance to Emb.[@b26-idr-12-579] We did not find any other mutations in the rest of the Emb-resistant MDR strains, and our results suggest that *embB*306 and *embC270* mutations do not cause Emb resistance in any MTB isolates, and other mutations, including the involvement of less common mutations in codons 406 and 497, should be considered for resistance to this antibiotic in isolates. Moreover, we cannot rule out a contribution of mutations outside the *embCAB* operon that could have been coselected during growth in the presence of Emb. Gene mutations only modestly increase resistance to Emb in MTB isolates. Our findings were in line with a previous study conducted by Safi et al,[@b27-idr-12-579] demonstrating that although *embB*306 mutations are necessary for Emb resistance, no resistant strains were detected by these mutations.

Although in this study the large number of MTB isolates (n=307) was investigated, the number of Emb-resistant isolates was quite low (n=10, 3.25%). However, according to previous reports from Iran, the resistance rate of MTB to Emb varied widely: from 1% in Tavanaee et al[@b28-idr-12-579] and 4.2% in Seif et al[@b29-idr-12-579] to as high as 14% in Farazi et al.[@b30-idr-12-579] Similarly, the prevalence of MDR in our study was also low (n=4, 1.30%), three of which showed coresistance to Emb as well, and in only one Emb-resistant MDR isolate did we find the 306 *embB* mutation.

Among the Emb phenotypic resistant isolates, only two were detected by mutations within the *embCAB* operon. The discordance between phenotypic AST of Emb and mutations in the *embCAB* operon has also been reported by investigators from other countries and Iran.[@b31-idr-12-579]--[@b33-idr-12-579] In the study from Iran, *embB* mutations were investigated in a few Iranian cities, and based on their results from four Emb-resistant isolates recovered from Tehran, only one 306 mutation was detected, and in some cities no 306 mutation was demonstrated among the phenotypic Emb-resistant isolates.[@b33-idr-12-579] In the current study, we investigated the most common mutation sites within the three genes *embA, embB*, and *embC*. Further studies should investigate other mutations within and outside this operon over an extended period, as other investigators have concluded that a few mutations conferring Emb resistance may occurred outside this operon.[@b13-idr-12-579]

Conclusion
==========

Few of our Emb-resistant isolates (n=8, 80%) were demonstrated by mutations in investigated sequences within the *embCAB* operon. As such, these mutations alone are insufficient for the development of full resistance to Emb in MTB strains. Additional mechanisms of resistance other than mutations in the current studied sequences within the *emb-CAB* operon should also be considered. Although this study demonstrates a low level of Emb resistance in our region, for the control of drug-resistance spread, regular monitoring is necessary to maintain a lower resistance rate, which is crucial for the treatment strategy and management of TB.
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###### 

Oligonucleotide primer sequences employed for amplification of the *embCAB* genes

  ----------------------------------------------------------------------------------------------
           Sequence                         Annealing temperature (°C)   PCR-product size (bp)
  -------- -------------------------------- ---------------------------- -----------------------
                                                                         

  *embA*   5′-GCCGGCTATGTAGCCAACTA-3′(F)\   63                           338
           5′-GACCGTTCCACCAACACC-3′(R)                                   

  *embB*   5′-CTGCTCTGGCATGTCAT-3′(F)\      48                           103
           5′-AGCGGAAATAGTTGGAC-3′(R)                                    

  *embC*   5′-GATACCCGCTACAGCAGCA-3′ (F)\   63                           334
           5′-GGTCGTAGTACCAGCCGAAA-3′(R)                                 
  ----------------------------------------------------------------------------------------------

###### 

Drug-susceptibility profile of resistance phenotypes among confirmed MTB isolates (n=307)

  Resistant-isolate code                           Inh         Rif          Emb
  ------------------------------------------------ ----------- ------------ ------------
                                                                            
  274                                              S           R            S
  281                                              S           R            S
  341                                              S           R            S
  410                                              S           R            S
  475                                              R           S            S
  577[\*](#tfn1-idr-12-579){ref-type="table-fn"}   R           R            R
  731[\*](#tfn1-idr-12-579){ref-type="table-fn"}   R           R            S
  924                                              S           R            S
  32                                               R           S            S
  646[\*](#tfn1-idr-12-579){ref-type="table-fn"}   R           R            R
  108                                              S           R            S
  67[\*](#tfn1-idr-12-579){ref-type="table-fn"}    R           R            R
  196                                              S           S            R
  642                                              S           S            R
  658                                              S           S            R
  288                                              S           S            R
  624                                              S           S            R
  41                                               S           S            R
  684                                              S           S            R
  Resistance rate, n (%)                           6 (1.95%)   10 (3.25%)   10 (3.25%)

**Note:**

MDR isolates.

**Abbreviations:** Emb, ethambutol; Inh, isoniazid; R, resistant; Rif, rifampicin; S, sensitive; MDR, multidrug-resistant.

###### 

Mutation pattern of *embCAB* genes in ten ethambutol-resistant isolates with different drug-resistance phenotypes

  Resistant-isolate code (S)    Affected codon   Resistance phenotype, Inh/Rif   Nucleotide change, *embA*   Nucleotide change, *embB*   Nucleotide change, *embC*
  ----------------------------- ---------------- ------------------------------- --------------------------- --------------------------- ---------------------------
                                                                                                                                         
  67                            306              +/+ (MDR)                       --                          Met to Val (ATG→ GTG)       --
  577                           None             +/+ (MDR)                       --                          --                          --
  646                           None             +/+ (MDR)                       --                          --                          --
  658                           270              −/−                             --                          --                          Thr to Ile (ACC→ATC)
  196, 642, 288, 624, 41, 684   None             −/−                             --                          --                          --

**Abbreviation:** MDR, multidrug-resistant.

###### 

Characteristics of ten ethambutol-resistant and 26 randomly selected ethambutol-susceptible MTB isolates with *embCAB* mutations

  Phenotype   Isolate code   *embA*                *embB*                *embC*
  ----------- -------------- --------------------- --------------------- ---------------------
                                                                         
  R (MDR)     67             Wild type             ATG→GTG (Met306Val)   Wild type
  R           658            Wild type             Wild type             ACC→ATC (Thr270Ile)
  R           196            Wild type             Wild type             Wild type
  R           642            Wild type             Wild type             Wild type
  R           288            Wild type             Wild type             Wild type
  R           624            Wild type             Wild type             Wild type
  R           41             Wild type             Wild type             Wild type
  R           684            Wild type             Wild type             Wild type
  R (MDR)     646            Wild type             Wild type             Wild type
  R (MDR)     577            Wild type             Wild type             Wild type
  S           732            CTG→TTG (Leu330Leu)   Wild type             Wild type
  S           427            Wild type             Wild type             Wild type
  S           71             Wild type             Wild type             Wild type
  S           731            Wild type             Wild type             Wild type
  S           753            Wild type             Wild type             Wild type
  S           893            Wild type             Wild type             Wild type
  S           520            Wild type             Wild type             Wild type
  S           416            Wild type             Wild type             Wild type
  S           30             Wild type             Wild type             Wild type
  S           848            Wild type             Wild type             Wild type
  S           66             Wild type             Wild type             Wild type
  S           919            Wild type             Wild type             Wild type
  S           668            Wild type             Wild type             Wild type
  S           969            Wild type             Wild type             Wild type
  S           924            Wild type             Wild type             Wild type
  S           303            Wild type             Wild type             Wild type
  S           109            Wild type             Wild type             Wild type
  S           104            Wild type             Wild type             Wild type
  S           128            Wild type             Wild type             Wild type
  S           20             Wild type             Wild type             Wild type
  S           744            Wild type             Wild type             Wild type
  S           86             Wild type             Wild type             Wild type
  S           14             Wild type             Wild type             Wild type
  S           935            Wild type             Wild type             Wild type
  S           108            Wild type             Wild type             Wild type
  S           600            Wild type             Wild type             Wild type

**Abbreviations:** MTB, *Mycobacterium tuberculosis*; MDR, multidrug-resistant.
